Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065370 | 0.92 | MEN1 (0.38) | MEN1KMT2ABACE1GPR119RBP4 | |
| SCHEMBL14945259 | 0.89 | MEN1 (0.38) | MEN1KMT2ABACE1GPR119RBP4 | |
| SCHEMBL15032343 | 0.87 | GPR119 (0.55) | MEN1KMT2AGPR119GAASMN1; SMN2 | |
| SCHEMBL517028 | 0.86 | RBP4 (0.38) | MEN1KMT2ABACE1RBP4GAA | |
| SCHEMBL29051803 | 0.84 | MEN1 (0.36) | MEN1KMT2ABACE1GPR119RBP4 | |
| SCHEMBL29052240 | 0.84 | MEN1 (0.36) | MEN1KMT2ABACE1GPR119RBP4 | |
| SCHEMBL29051800 | 0.84 | MEN1 (0.36) | MEN1KMT2ABACE1GPR119RBP4 | |
| SCHEMBL20744142 | 0.84 | POLB (0.39) | MEN1KMT2ACHRM1ALDH1A1HPGD | |
| SCHEMBL15603256 | 0.82 | RIPK1 (0.36) | MEN1KMT2ABACE1CHRM3ACHE | |
| SCHEMBL30468471 | 0.82 | GRM5 (0.43) | MEN1KMT2AGPR119RBP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-8470811-B2 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | HIF1AN, VHL, HIF1A | MEN1 1887/4885KMT2A 3186/4885BACE1 2264/4885 |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | VHL, HIF1AN, HIF1A | MEN1 1673/4885KMT2A 2770/4885BACE1 3281/4885 |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | HIF1AN, VHL, HIF1A | MEN1 2008/4885KMT2A 3082/4885BACE1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.